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INTRODUCTION
Intrauterine growth restriction (IUGR) is a lead-
ing cause of perinatal morbidity and mortality. 
Low birth weight resulting from preterm birth 
and/or IUGR is an underlying factor in 60-80% 
of perinatal death worldwide, and is particular-
ly common in developing countries (UNICEF, 
2008). Furthermore, studies have linked IUGR 
and the associated fetal malnutrition to increased 
incidence of metabolic syndrome in adult life 
(Barker et al., 1993; Godfrey and Barker, 2000). 
The “thrifty phenotype hypothesis” developed 
by David Barker (Hales et al., 1991) states that 
IUGR-associated fetal malnutrition forces the fe-
tus to spare nutrients by altering tissue-specific 
metabolism in order to survive. In utero, adaptive 
changes disproportionately impact skeletal mus-
cle development, growth, and metabolism (Yates 
et al., 2016). Skeletal muscle is responsible for the 
majority of insulin-stimulated glucose utilization, 
and adaptive restriction in muscle growth capacity 
helps to spare glucose in the IUGR fetus but result 
in lifelong deficits in muscle mass and metabol-
ic homeostasis (Brown and Hay, 2016). Skeletal 
muscle growth requires proliferation, differen-
tiation, and fusion of myoblast into new muscle 
fibers early in gestation and fusion with existing 
fibers in the third trimester of pregnancy (Zhu et 
al., 2004). This process can be impaired by inflam-
mation from resident macrophages within skeletal 
muscle. Classically-activated M1 macrophages 
are pro-inflammatory but can polarize to an anti-
inflammatory M2 phenotype that inhibits cytokine 
production and stimulates tissue repair by pro-
ducing growth factors (Mantovani et al., 2004; 
Kharraz et al., 2013). The acute effects of inflam-
matory factors on myoblast function have been 
investigated in vitro (Frost et al., 1997; Guttridge 
et al., 2000), and we postulate that inflammatory 
stress may have similar effects on fetal myoblasts 
in utero. Impaired myoblast function and the re-
sulting decrease in muscle growth capacity affect 
long-term metabolic health. Therefore, the objec-
tive of this study was to determine the effect of 
sustained maternal inflammation at mid-gestation 
on fetal mortality, muscle growth, and metabolic 
parameters at term. 
MATERIALS AND METHODS
Animals and experimental design
Animal use and care was approved by the 
Institutional Animal Care and Use Committee at 
the University of Nebraska-Lincoln. Animal stud-
ies were performed at the University of Nebraska-
Lincoln Animal Science Complex, which is 
accredited by the American Association for 
Accreditation of Laboratory Animal Care. From 
day 9 to 11 of gestation, time-mated Sprague-
Dawley rats (Envigo, Indianapolis, IN) received 
daily i.p. injections of saline (n = 6) or 100μg/
kg BW lipopolysaccharide (LPS, n = 7) from E. 
coli 055:B5 (Sigma-Aldrich). Rats were weighed 
daily, and maternal blood was collected and rec-
tal temperature recorded throughout the treat-
ment period. On day 20 of gestation, dams were 
euthanized by decapitation under heavy isoflurane 
anesthesia. Fetal mass and number were recorded 
and maternal and fetal blood samples were col-
lected. Fetal hind limbs were collected from three 
randomly-selected fetuses per litter. For each fetus 
Maternal inflammation at mid-gestation in pregnant rats impairs  
fetal muscle growth and development at term
C. N. Cadaret,* K. A. Beede,* E. M. Merrick,* T. L. Barnes,* J. D. Loy,† and D. T. Yates*1
*Department of Animal Science and †School of Veterinary Medicine and Biomedical Sciences,  
University of Nebraska-Lincoln, Lincoln 68583
1Coresponding author: dustin.yates@unl.edu
doi: 10.2527/asasws.2017.0032
ProceeD iNgS,  WeSterN Sect ioN    |    AMer icAN Soc iety  of  AN iMAL  Sc ieNce    |    VOLUME 68, 2017
Published online September 28, 2017
Proceedings, Western Section, American Society of Animal Science 203
one hind limb was fixed in 4% PFA and the other was 
snap-frozen.
Blood analysis
 Maternal and fetal blood glucose concentrations 
were determined at necropsy (Bayer Glucose Meter). 
Plasma was isolated by centrifugation (14,000 x g, 2 
min) and TNFα concentrations were determined by 
Quantikine ELISA kit (R&D Systems) as previously 
described (Seo et al., 2017). Inter-assay CV was less 
than 10%. 
Gene expression
Droplet digital PCR. RNA was extracted from fetal 
hind limb (30 mg) via RNeasy Fibrous Tissue Mini Kit 
(Qiagen), quantified by spectrophotometry (NanoDrop 
Technologies), and reverse transcribed via QuantiTect 
Reverse Transcription Kit (Qiagen). Primers for PCR 
were designed and droplet digital PCR (ddPCR) was 
performed with the QX200 ddPCR System (BioRad). 
Each reaction contained Evagreen Supermix, 10μM of 
each primer, and 1 μL of cDNA template. Droplets were 
generated in a QX200 Droplet Generator with Droplet 
Generator Oil, transferred to a PCR plate, sealed, and 
placed in a C1000 Touch Thermal Cycler. Samples 
were activated (95°C for 5 min), denatured for 40 
cycles (95°C for 30 s), annealed and extended for 40 
cycles (60°C for 1 min), and stabilized (4°C for 5 min 
and 90°C for 5 min). Finally, droplets were read on the 
QX200 Droplet Reader and results were analyzed with 
QuantaSoft Software to obtain copies/μL for genes of 
interest. Results for CD68, CD163, TNFR1, IL6R, in-
sulin receptor β, and adrenergic receptors β1 and β2 
were then normalized to the Ywhaz gene, which was 
shown to be stable across treatment groups.
Quantitative PCR. Expression of CD68 and CD163 
was also measured via qPCR by the UNL Veterinary 
Diagnostic Center. RNA was extracted and cDNA was 
generated as described above. Template cDNA was 
standardized to 100 ng/reaction. Relative mRNA ex-
pression was determined using Power SYBR Green 
PCR Master Mix kits (Applied Biosystems) and ran 
on the Fast 7500 real-time PCR System. Samples were 
initially denatured (10 min at 95°C), followed by 40 
cycles of 95°C for 15s, and an annealing and exten-
sion phase at 60°C for 1 min. mRNA expression was 
determined in triplicate from cDNA and normalized to 
the concentration of the housekeeping gene β-actin the 
using 2- Δ ΔCt method.
Immunohistochemistry
Fixed fetal hind limbs were embedded in OCT 
Compound (Thermo-Fisher) and 8μm cross sections 
were cut and mounted on glass microscope slides. 
Slides were dried at 37°C for 30 min and then thrice 
washed in PBS + 0.5% Triton-X-100. Antigen re-
trieval was performed by boiling slides in 10 mM 
citric acid for 20 minutes. Non-specific binding was 
blocked with 0.5% NEN blocking buffer (Perkin-
Elmer) at room temperature for 1 hr. Slides were 
then incubated overnight at 4°C with primary anti-
bodies diluted in PBS + 1% Bovine Serum Albumin. 
Negative controls were incubated without primary 
antibody. Sections were stained with rabbit antibody 
against myf5 (1:100; Santa Cruz), and mouse antibod-
ies against myoD (1:200, Dako) and myogenin (1:250, 
Abcam) to identify nuclei expressing these myogenic 
factors. Macrophage profiles were determined by co-
staining for total macrophages (CD68, 1:50; Abcam) 
and M2 macrophages (CD163, 1:100; Abcam). All 
nuclei were identified by counterstaining with DAPI 
(1:2000, Sigma-Aldrich). Immunocomplexes were de-
tected with Alexa Fluor 594 (1:2000; Cell Signaling) 
or Alexa Fluor 488 (1:1000). Staining was visualized 
on an Olympus IX73 and digital micrographs were 
captured with a DP80 microscope camera (Olympus). 
Images were analyzed with CellsSens Dimension 
software to determine proportions of positive nuclei 
within fetal skeletal muscle sections. Animal identifi-
cations and treatments were encoded to eliminate bias. 
Statistical analysis
All data were analyzed by ANOVA using the GLM 
procedure of SAS (SAS Institute) to determine treat-
ment effects. Dam was the experimental unit. Skeletal 
muscle mRNA concentrations from ddPCR are ex-
pressed as copies per copy of Ywhaz. Macrophage 
mRNA concentrations analyzed by qPCR were nor-
malized to β-actin and are expressed relative to the 
controls. All data are expressed as means ± standard 
error. Proportions of nuclei positive for myogenic fac-
tors and macrophage markers were determined from 
an average of 250 and 850 positive nuclei, respective-
ly, counted across 18 fields of view. 
RESULTS
Morphometrics and blood analysis
The number of fetuses per litter did not differ 
between control and LPS-treated rats, but fetal mass 
was reduced (P < 0.10) in LPS fetuses (71.4±2.8 and 
60.8±2.8, respectively). Maternal blood glucose was 
reduced (P < 0.05) in LPS-treated rats 12 hours after 
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the first daily injection but did not differ from con-
trols otherwise (data not shown). Maternal plasma 
TNFα was greater (P < 0.05) in LPS-treated rats six 
hours after the first daily injection but did not differ 
from controls otherwise (data not shown). Fetal blood 
glucose at necropsy did not differ between treatments 
(data not shown), but LPS rats tended to have greater 
(P < 0.10) fetal plasma TNFα than controls (0.02±0.26 
and 0.83±0.29 pg/ml, respectively). 
Skeletal muscle gene expression
When measured by qPCR, CD68 mRNA expres-
sion was decreased (P < 0.05) in LPS fetal muscle but 
CD163 mRNA did not differ between treatments (Figure 
1). When measured by ddPCR, CD68 mRNA concen-
trations tended to be decreased (P < 0.10) and CD163 
concentrations were decreased (P < 0.05) in LPS fetal 
muscle compared to controls. TNFR1 and IL6R mRNA 
tended to be reduced (P < 0.10) in LPS fetal muscle as 
well (Figure 2). No differences were observed for insu-
lin receptor or β adrenergic receptor gene expression.
Skeletal muscle immunohistochemistry
CD68-positive nuclei/μm2 tended to be decreased 
(P < 0.10) in LPS fetal muscle compared to controls 
but CD163-positive nuclei/μm2 were not different 
(Figure 3). Likewise, the proportion of CD68-positive 
nuclei–to-CD163-postive nuclei did not differ between 
treatments (0.94±0.20 vs. 1.24±0.24, respectively). 
MyoD-positive nuclei/μm2 were decreased (P < 0.05) 
and myogenin-positive nuclei tended to be greater (P 
< 0.10) in LPS fetal hind limb muscle (Figure 4), but 
myf5-postive nuclei/μm2 did not differ between treat-
ments (128.4±28.5 vs. 92.0±24.1, respectively). 
DISCUSSION
In the present study, we show that reduced fetal growth 
is a consequence of maternal inflammation at mid-ges-
tation. This decrease in fetal mass near term appears to 
be the result of restricted skeletal muscle growth capac-
ity, as reduced myoD and increased myogenin in hind 
limb muscle was indicative of impaired myoblast func-
tion. Fetuses from LPS-treated dams had higher concen-
trations of circulating TNFα near term, which indicates 
that greater inflammation may be responsible for reduc-
tions in myoblast-induced fetal skeletal muscle growth. 
Additionally, increased circulating cytokines were ac-
companied by decreases in skeletal muscle TNFR and 
IL6R mRNA, which together with decreased myoD and 
increased myogenin indicate a compensatory decrease in 
cytokine sensitivity due to chronically high circulating 
inflammatory cytokines. These findings indicate that sus-
tained maternal inflammation at mid-gestation impairs 
fetal skeletal muscle growth near term due to changes in 
myoblast responsiveness to critical cytokine regulation. 
Fetal mass was decreased late in gestation follow-
ing sustained maternal inflammation, likely due to de-
creases in skeletal muscle mass. We attribute decreased 
skeletal muscle growth to impaired myoblast function, 
as myoD was decreased and myogenin was increased in 
fetuses from LPS-treated dams. The absence of myoD 
results in impaired myoblast function, as myoblasts 
will continue to proliferate rather than exiting the cell 
cycle and fusing with fibers (Rudnicki et al., 1993). The 
combination of decreased myoD and increased myo-
Figure 1. Gene expression analysis for total and M2 macrophage markers in fetal hind limb as measured by qPCR (A) and ddPCR (B) * means dif-
fered (P < 0.05) between control and LPS fetuses. # means tended to differ (P < 0.10) between control and LPS fetuses. 
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genin indicates a greater percentage of differentiated 
myoblasts but a reduced percentage of active prolif-
erating myoblast. This imbalance in MRF expression 
represents an imbalance in the myogenic cell popula-
tion and, ultimately, a deficient muscle growth capacity. 
Additionally, maternal inflammation resulted in higher 
concentrations of TNFα in fetal plasma, well after treat-
ment ended. TNFα has been shown to impede differen-
tiation and fusion of myoblasts at high concentrations 
(Miller et al., 1988). High fetal inflammatory cytokines 
reduced TNFR and IL6R in skeletal muscle, indicating 
a reduced sensitivity to these important regulators of 
skeletal muscle. Reduced sensitivity impedes the ability 
of cytokines to elicit a regulatory effect on myoblasts 
and causes an imbalance between proliferation and dif-
ferentiation by allowing precocious differentiation.
Interestingly, increased circulating TNFα concen-
trations and decreased skeletal muscle cytokine sensi-
tivity was not the result of greater numbers of resident 
macrophages, as mRNA and protein markers showed 
decreased total macrophage populations, but no differ-
ence in M2 macrophage population in fetal hind limb 
after maternal inflammation. However, these fetal mac-
rophages are still producing greater amounts of inflam-
matory cytokines 10 days after maternal inflammation 
has subsided. Although it is not certain whether these 
inflammatory cytokines are from placental or fetal ori-
gin, the temporal spacing between induction of maternal 
inflammation and fetal plasma TNFα response suggest 
they are not of maternal origin. Moreover, since fetal 
TNFα is greater despite decreased macrophage number, 
it appears that fetal M1 macrophages have increased ac-
tivity. As a compensatory action for chronic exposure 
to inflammatory cytokines in LPS fetuses, the major 
cytokine receptors were decreased in skeletal muscle. 
Inflammatory cytokines bind to these receptors and ac-
tivate the NF-ĸB signaling pathway to upregulate gene 
expression of additional inflammatory cytokines, che-
mokines, and other inflammatory factors (Pahl, 1999). 
Activation of this pathway is responsible for the inhibi-
tory effect of cytokines on myoblast differentiation and 
thus reduced sensitivity at the level of the receptor may 
explain the increase in myoblast differentiation and 
concurrent reduction in proliferating myoblast. 
Fetal inflammation may be a direct response to 
maternal inflammation or may be indirectly caused by 
placental insufficiency. Maternal TNFα was acutely el-
evated in response to LPS treatment but did not differ 
from controls at day 20 of gestation when fetuses were 
collected, and in fact was not different on the second and 
third days of LPS administration. Fetal circulating TNFα 
was increased at term, suggesting fetal inflammation is 
Figure 2. Gene expression analysis (ddPCR) of TNFR1 (A) and IL6R (B) in fetal hind limb after maternal inflammation. # means tended to differ (P 
< 0.10) between control and LPS fetuses. 
Figure 3. A. Immunostaining of markers for total (CD68) and M2 
(CD163) macrophages in cross-sections of fetal hind limb muscle after ma-
ternal inflammation. A. Representative micrographs are depicted for con-
trol and LPS fetal hind limb cross sections (8μm). Sections were co-stained 
for total (green) and M2 (red) macrophages and counterstained with DAPI 
(blue). B. Analysis of positive total and M2 macrophages. # means differed 
(P < 0.10) between control and LPS fetuses. 
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most likely due to placental insufficiency. Additionally, 
previous studies found that inflammatory cytokines do 
not typically pass the placental barrier (Aaltonen et al., 
2005), indicating that all cytokines within the fetus and 
amniotic fluid are of conceptus origin.
In conclusion, maternal inflammation at mid-gesta-
tion results in decreased fetal mass due to impaired myo-
genesis that is still apparent at term. We demonstrate that 
impaired myogenesis is due to myoblast dysfunction as 
evident by decreased myoD and increased myogenin. 
Moreover, myoblast dysfunction is the likely result of 
increased inflammatory cytokines and the resultant de-
creased sensitivity to these cytokines. The inflammatory 
response may be due to amplified activity of M1 macro-
phages, as macrophage number was actually decreased 
in fetal skeletal muscle after maternal inflammation. 
Together, our findings show that maternal inflammation 
induces fetal adaptive responses that interrupt myoblast 
regulation, causing myoblast dysfunction and impaired 
skeletal muscle development and growth. 
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Figure 4. A. Immunostaining of myoD and myogenin in fetal hind limb muscles after maternal inflammation. Representative micrographs are de-
picted for control and LPS fetal hind limb cross sections (8 μm). Sections were stained for myoD (red) or myogenin (green) and counterstained with DAPI 
(blue). B. Analysis of myoD and myogenin positive nuclei. * means differed (P < 0.05) between control and LPS fetuses. # means differed (P < 0.10) 
between control and LPS fetuses.
